Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors

#567

Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.

Aim(s): To assess the efficacy of combined PRRNT and RFA in the management of hepatic metastases of NET.

Materials and methods: Nine patients of known metastatic GEP-NET underwent PRRNT (2-5 cycles with Lu-177 and/or Y-90 labeled DOTATATE/DOTATOC) before or after RFA for hepatic metastases. All patients had undergone SSTR PET/CT using Ga-68 DOTATOC before and after the therapies and also for follow-up.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Hommann M,

Keywords: Peptide receptor radionuclide therapy, radiofrequency ablation,